Trial Profile

A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 25 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti HER2 small molecule imaging agent (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
Focus Diagnostic use
Acronyms Affibody-3

24 Mar 2024 This trial has been Discontinued in Sweden (End date: 2024-02-05) according to European Clinical Trials Database record.
01 Sep 2023 Results investigating how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC, published in the Journal of Nuclear Medicine
09 Dec 2021 According to an Affibody media release, data presented at the San Antonio Breast Cancer Symposium 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com